Restylane Products Explained: Kysse, Lyft, Defyne, Refyne, Contour, Eyelight, Silk

Original Restylane is the founding product of the line.

FDA approved it on March 25, 2005, as Galderma's NASHA gel, for correction of moderate to severe facial wrinkles and folds such as nasolabial folds.

A lip indication followed on October 11, 2011 — submucosal implantation for lip augmentation, in patients over 21.

Restylane-L is that gel with lidocaine added, and FDA approved it for the same lip use on August 30, 2012.

Restylane Silk followed on June 13, 2014, with two approved uses in patients over 21: submucosal lip augmentation and correction of perioral lines, the lines around the lips.

In October 2017, FDA also approved a small-bore blunt cannula for Silk lip augmentation.

Outside the uses each label names, a use is off-label: it is not on any current US label for that product.

FDA approved Restylane Kysse on March 26, 2020 — the most recent of the lip approvals in this family — for lip augmentation and for correction of upper perioral lines, the small vertical lines just above the upper lip, in patients over 21.

Those two uses are the only Kysse indications in the approval record we reviewed.

On Galderma's own site, Kysse is one of the two products the company maps to lips, alongside Silk.

For the pivotal trial week by week, the volumes the trial used and the cost picture, see the Restylane Kysse guide.

Restylane Lyft holds the widest approval list in the family: moderate to severe facial folds such as nasolabial folds; cheek augmentation and correction of age-related midface contour deficiencies (July 1, 2015); volume deficit in the back of the hands (May 18, 2018); and augmentation of the chin region to improve the chin profile in mild to moderate chin retrusion (November 4, 2025).

Every one of those approvals names patients over 21.

The jawline is not among them.

As of October 2026, the only US fillers with a jawline indication are Juvéderm Volux XC (2022) and Radiesse (+) (2021), so jawline use is off-label for every Restylane product, Lyft included.

The Lyft label also sets per-treatment maximums: 6.0 mL for wrinkles and folds, 6.0 mL for the cheek or midface, 3.0 mL per hand, and 4 mL for the chin including touch-up, with no more than 2 mL per injection site.

Those are safety ceilings, not typical or recommended amounts.

In the Lyft chin trial, blinded evaluators rated 83.6% of Lyft subjects improved by at least one grade at month 3, 75.5% at month 6 and 69.7% at month 12; the trial measured Lyft against a comparator chin filler and found it non-inferior.

For chin filler as a treatment — candidacy, technique and cost — the chin filler guide has the details.

Restylane Refyne and Restylane Defyne were approved together on December 9, 2016, for moderate to severe facial wrinkles and folds such as nasolabial folds, in patients over 21.

The wording differs on depth: Defyne's indication specifies deep wrinkles and folds; Refyne's does not.

Refyne has no chin or lip indication.

Defyne added a chin use on January 29, 2021 — augmentation of the chin region to improve the chin profile in patients with mild to moderate chin retrusion, over 21.

The Defyne label caps a chin treatment at 4 mL per patient: 2 mL in the chin plus 2 mL below the lower lip, toward the pre-jowl sulcus.

In the Defyne chin trial, 86.1% of treated subjects showed at least a 1-point chin-profile improvement at week 12, against 6.5% of untreated controls, and the difference was still significant at week 48.

That trial result is a group figure, not what any one patient gets.

Restylane Contour is the family's cheek-and-temple product.

FDA approved it on June 28, 2021, for cheek augmentation and correction of midface contour deficiencies in patients over 21, and expanded the label on March 20, 2026, to correction of temple hollowing.

The label caps a treatment session at 6 mL in the cheeks and midface and at up to 3 mL per temple.

In the cheek trial, the median volume for initial treatment plus touch-up was 3.80 mL, and the median at re-treatment at week 48 was 1.95 mL — trial medians, not a standard dose.

Contour's cheek trial was also a head-to-head study: Galderma randomized Contour against Juvéderm Voluma XC at a 2:1 ratio, treated with a needle.

Blinded-evaluator responder rates were 91.2% versus 87.7% at week 12, 88.5% versus 83.1% at week 24, 72.1% versus 83.6% at week 36 and 62.8% versus 65.1% at week 48, Contour versus Voluma.

Those are similar results that traded places over time, in a trial run by Contour's own maker and designed to test similarity rather than superiority — neither product comes out of it clearly ahead.

In the temple trial, blinded-evaluator responder rates for temple hollowing were 91.9% at month 3, 94.6% at month 6, 92.8% at month 9, 91.6% at month 12 and 86.1% at month 18 — rates for Contour in its own trial, not a promise of how long any filler lasts in the temples.

Restylane Eyelight is the family's under-eye product.

FDA approved it on May 8, 2023 — a supplement to the same premarket approval original Restylane holds — for improvement of infraorbital (under-eye) hollowing in patients over 21.

The indication is the hollow, not dark-circle pigment.

Galderma's site promotes Eyelight to "correct dark circles," but the approval covers hollowing only, and the product's own label warns that injecting under the eyes in people with pigmented dark circles may make the discoloration look more prominent.

As of October 2026, Eyelight is the only Restylane product among the four US fillers with an approved infraorbital-hollow indication — the other three are Juvéderm Volbella XC, Belotero Balance (+) Lidocaine and RHA Redensity Eye / Eye Lido — so any other Restylane gel placed under the eyes is off-label there.

For the label's session limits, the trial's responder curve and the recovery figures, see the Restylane Eyelight guide.

Galderma's own site maps the US line by area: Kysse and Silk for lips; Lyft and Contour for cheeks; Defyne for the chin; Defyne, Lyft, Refyne and Restylane for smile lines; Lyft for the backs of the hands; Eyelight for under-eye hollows; and Contour, announced on the site as approved for temple hollowing.

That map is the maker's marketing, and it can lag the approval record: when the site was read for this guide in October 2026, it still routed chin questions to Defyne alone, although FDA had approved Lyft for the chin in November 2025.

The PMA record, not the brochure, is the list to check.

Used outside a product's own approvals, any filler is off-label — the use is on no current US label for that product.

That is why both the product and the area belong in the consultation: a licensed provider can say which Restylane product, if any, is approved for the area you want treated, and what an off-label plan would mean in your case.

For what the line costs, how long results hold, side effects and finding an injector, the Restylane guide covers the family end to end.